Trials / Terminated
TerminatedNCT00947167
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Pamela L. Kunz · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To determine objective response rates (RR) by RECIST guideline version 1.1 for all patients treated with this strategy consisting of initial therapy with pertuzumab as a single agent and then addition of erlotinib for those who have stable disease or progressive disease at three months (Simon design).
Conditions
- Neuroendocrine Tumors
- Carcinoid Tumors
- Adrenal Gland Tumors
- Neuroblastoma
- Pancreatic Neuroendocrine Tumors
- Multiple Endocrine Neoplasia
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pertuzumab | 840 mg, 420 mg, iv |
| DRUG | erlotinib | 150 mg, PO |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2010-05-01
- Completion
- 2010-05-01
- First posted
- 2009-07-27
- Last updated
- 2017-03-03
- Results posted
- 2017-03-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00947167. Inclusion in this directory is not an endorsement.